Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model

Schizophrenia Research

Volumn 151, Issue 1-3, 2013, Pages 20-28

  Seki, Yoshihiro ^a   Kato, Takahiro A ^a,b   Monji, Akira ^a,c   Mizoguchi, Yoshito ^c   Horikawa, Hideki ^a   Sato Kasai, Mina ^a   Yoshiga, Daigo ^d   Kanba, Shigenobu ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Antipsychotics; Interferon gamma (IFN ); Microglia; Minocycline; Nitric oxide; Oligodendrocyte; Schizophrenia; Tumor necrosis factor alpha (TNF )

Indexed keywords

ARIPIPRAZOLE; GAMMA INTERFERON; HALOPERIDOL; MINOCYCLINE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIPSYCHOTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DAMAGE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROGLIA; MOLECULAR DYNAMICS; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANTIPSYCHOTICS; INTERFERON-GAMMA (IFN-Γ); MICROGLIA; MINOCYCLINE; NITRIC OXIDE; OLIGODENDROCYTE; SCHIZOPHRENIA; TUMOR NECROSIS FACTOR-ALPHA (TNF-Α);

ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BENZOXAZOLES; BRAIN; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG INTERACTIONS; HALOPERIDOL; INTERFERON-GAMMA; MICROGLIA; MINOCYCLINE; MYELIN PROTEOLIPID PROTEIN; NITRITES; OLIGODENDROGLIA; PIPERAZINES; QUINOLINIUM COMPOUNDS; QUINOLONES; RATS; STAT1 TRANSCRIPTION FACTOR;

EID: 84889090841     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.09.011     Document Type: Article

References (84)

1. Ahuja N., Carroll B.T. Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:968-969.
2. Bartzokis G., Lu P.H., Nuechterlein K.H., Gitlin M., Doi C., Edwards N., Lieu C., Altshuler L.L., Mintz J. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr. Res. 2007, 93:13-22.
3. Bartzokis G., Lu P.H., Stewart S.B., Oluwadara B., Lucas A.J., Pantages J., Pratt E., Sherin J.E., Altshuler L.L., Mintz J., Gitlin M.J., Subotnik K.L., Nuechterlein K.H. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res. 2009, 113:322-331.
4. Bartzokis G., Lu P.H., Raven E.P., Amar C.P., Detore N.R., Couvrette A.J., Mintz J., Ventura J., Casaus L.R., Luo J.S., Subotnik K.L., Nuechterlein K.H. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr. Res. 2012, 140:122-128.
5. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68:843-853.
6. Bernstein H.G., Steiner J., Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert. Rev. Neurother. 2009, 9:1059-1071.
7. Bi W., Zhu L., Wang C., Liang Y., Liu J., Shi Q., Tao E. Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res. 2011, 1395:12-20.
8. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., Kanba S. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:42-48.
9. Buntinx M., Gielen E., Van Hummelen P., Raus J., Ameloot M., Steels P., Stinissen P. Cytokine-induced cell death in human oligodendroglial cell lines. II: alterations in gene expression induced by interferon-gamma and tumor necrosis factor-alpha. J. Neurosci. Res. 2004, 76:846-861.
10. Cammer W., Zhang H. Maturation of oligodendrocytes is more sensitive to TNF alpha than is survival of precursors and immature oligodendrocytes. J. Neuroimmunol. 1999, 97:37-42.
11. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26:1185-1193.
12. Chaves C., de Marque C.R., Wichert-Ana L., Maia-de-Oliveira J.P., Itikawa E.N., Crippa J.A., Zuardi A.W., Todd K.G., Baker G.B., Dursun S.M., Hallak J.E. Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:550-552.
13. Cheepsunthorn P., Radov L., Menzies S., Reid J., Connor J.R. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 2001, 35:53-62.
14. Chen Y., Balasubramaniyan V., Peng J., Hurlock E.C., Tallquist M., Li J., Lu Q.R. Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat. Protoc. 2007, 2:1044-1051.
15. Cui Y., Wu J., Jung S.C., Kim G.O., Kyeong Ko R., Lee H.J., Yoo E.S., Kang H.K., Suk K., Eun S.Y. Neuroprotective effect of methyl lucidone against microglia-mediated neurotoxicity. Eur. J. Pharmacol. 2012, 690:4-12.
16. Defaux A., Zurich M.G., Honegger P., Monnet-Tschudi F. Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-gamma plus lipopolysaccharide-induced demyelination. Neuroscience 2011, 187:84-92.
17. Dentesano G., Straccia M., Ejarque-Ortiz A., Tusell J.M., Serratosa J., Saura J., Sola C. Inhibition of CD200R1 expression by C/EBP beta may constitute an effort to revascularize and oxygenate the tissue in reactive microglial cells. J. Neuroinflammation 2012, 9:165.
18. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50:1801-1807.
19. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14669-14674.
20. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., Van Nostrand W.E. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 2007, 27:3057-3063.
21. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35:528-548.
22. Feldhaus B., Dietzel I.D., Heumann R., Berger R. Effects of interferon-gamma and tumor necrosis factor-alpha on survival and differentiation of oligodendrocyte progenitors. J. Soc. Gynecol. Investig. 2004, 11:89-96.
23. Freudenreich O., Brockman M.A., Henderson D.C., Evins A.E., Fan X., Walsh J.P., Goff D.C. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010, 176:99-102.
24. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:336-339.
25. Giuliani F., Hader W., Yong V.W. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J. Leukoc. Biol. 2005, 78:135-143.
26. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFNgamma signaling - does it mean JAK-STAT?. Cytokine Growth Factor Rev. 2008, 19:383-394.
27. Gresa-Arribas N., Vieitez C., Dentesano G., Serratosa J., Saura J., Sola C. Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents. PLoS One 2012, 7:e45227.
28. Horvath R.J., Nutile-McMenemy N., Alkaitis M.S., Deleo J.A. Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J. Neurochem. 2008, 107:557-569.
29. Jaaro-Peled H., Hayashi-Takagi A., Seshadri S., Kamiya A., Brandon N.J., Sawa A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 2009, 32:485-495.
30. Jakovcevski I., Zecevic N. Sequence of oligodendrocyte development in the human fetal telencephalon. Glia 2005, 49:480-491.
31. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., Archibald D., Ingenito G., Marcus R., Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 2003, 6:325-337.
32. Kato T., Monji A., Hashioka S., Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 2007, 92:108-115.
33. 2+ regulation in vitro. J. Neurochem. 2008, 106:815-825.
34. Kato T.A., Monji A., Mizoguchi Y., Hashioka S., Horikawa H., Seki Y., Kasai M., Utsumi H., Kanba S. Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?. Mini Rev. Med. Chem. 2011, 11:565-574.
35. Kato T.A., Monji A., Yasukawa K., Mizoguchi Y., Horikawa H., Seki Y., Hashioka S., Han Y.H., Kasai M., Sonoda N., Hirata E., Maeda Y., Inoguchi T., Utsumi H., Kanba S. Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia. Schizophr. Res. 2011, 129:172-182.
36. Kato T.A., Yamauchi Y., Horikawa H., Monji A., Mizoguchi Y., Seki Y., Hayakawa K., Utsumi H., Kanba S. Neurotransmitters, psychotropic drugs and microglia: clinical implications for psychiatry. Curr. Med. Chem. 2013, 20:331-344.
37. Kawanokuchi J., Mizuno T., Takeuchi H., Kato H., Wang J., Mitsuma N., Suzumura A. Production of interferon-gamma by microglia. Mult. Scler. 2006, 12:558-564.
38. Keck P.E., Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., Marcus R.N., Sanchez R., Aripiprazole Study G. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 2006, 67:626-637.
39. Kelly D.L., Vyas G., Richardson C.M., Koola M., McMahon R.P., Buchanan R.W., Wehring H.J. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr. Res. 2011, 133:257-258.
40. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., Leonard B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1129-1134.
41. Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10:268-278.
42. Kubota M., Miyata J., Yoshida H., Hirao K., Fujiwara H., Kawada R., Fujimoto S., Tanaka Y., Sasamoto A., Sawamoto N., Fukuyama H., Murai T. Age-related cortical thinning in schizophrenia. Schizophr. Res. 2011, 125:21-29.
43. Kubota M., Miyata J., Sasamoto A., Sugihara G., Yoshida H., Kawada R., Fujimoto S., Tanaka Y., Sawamoto N., Fukuyama H., Takahashi H., Murai T. Thalamocortical disconnection in the orbitofrontal region associated with cortical thinning in schizophrenia. JAMA Psychiatry 2013, 70:12-21.
44. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71:138-149.
45. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9936-9941.
46. Li J., Ramenaden E.R., Peng J., Koito H., Volpe J.J., Rosenberg P.A. Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J. Neurosci. 2008, 28:5321-5330.
47. McCullumsmith R.E., Gupta D., Beneyto M., Kreger E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr. Res. 2007, 90:15-27.
48. Miller B.A., Crum J.M., Tovar C.A., Ferguson A.R., Bresnahan J.C., Beattie M.S. Developmental stage of oligodendrocytes determines their response to activated microglia in vitro. J. Neuroinflammation 2007, 4:28.
49. Mittelbronn M., Dietz K., Schluesener H.J., Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 2001, 101:249-255.
50. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol. Disord. Drug Targets 2008, 7:376-381.
51. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:304-307.
52. Miyata J., Hirao K., Namiki C., Fujiwara H., Shimizu M., Fukuyama H., Sawamoto N., Hayashi T., Murai T. Reduced white matter integrity correlated with cortico-subcortical gray matter deficits in schizophrenia. Schizophr. Res. 2009, 111:78-85.
53. Mizoguchi H., Takuma K., Fukakusa A., Ito Y., Nakatani A., Ibi D., Kim H.C., Yamada K. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl.) 2008, 196:233-241.
54. Nikodemova M., Duncan I.D., Watters J.J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J. Neurochem. 2006, 96:314-323.
55. Nikodemova M., Watters J.J., Jackson S.J., Yang S.K., Duncan I.D. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/beta II. J. Biol. Chem. 2007, 282:15208-15216.
56. Paterson G.J., Ohashi Y., Reynolds G.P., Pratt J.A., Morris B.J. Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. J. Psychopharmacol. 2006, 20:636-642.
57. Plane J.M., Shen Y., Pleasure D.E., Deng W. Prospects for minocycline neuroprotection. Arch. Neurol. 2010, 67:1442-1448.
58. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
59. Price S.J., Jena R., Burnet N.G., Hutchinson P.J., Dean A.F., Pena A., Pickard J.D., Carpenter T.A., Gillard J.H. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am. J. Neuroradiol. 2006, 27:1969-1974.
60. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59:137-150.
61. Renaud S., Hays A.P., Brannagan T.H., Sander H.W., Edgar M., Weimer L.H., Olarte M.R., Dalakas M.C., Xiang Z., Danon M.J., Latov N. Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 2005, 159:203-214.
62. Rutault K., Hazzalin C.A., Mahadevan L.C. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J. Biol. Chem. 2001, 276:6666-6674.
63. Schlosser R.G., Nenadic I., Wagner G., Gullmar D., von Consbruch K., Kohler S., Schultz C.C., Koch K., Fitzek C., Matthews P.M., Reichenbach J.R., Sauer H. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr. Res. 2007, 89:1-11.
64. Schnieder T.P., Dwork A.J. Searching for neuropathology: gliosis in schizophrenia. Biol. Psychiatry 2011, 69:134-139.
65. Steelman A.J., Li J. Poly(I:C) promotes TNFalpha/TNFR1-dependent oligodendrocyte death in mixed glial cultures. J. Neuroinflammation 2011, 8:89.
66. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., Bogerts B. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 2006, 112:305-316.
67. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., Brisch R., Gos T., Mawrin C., Myint A.M., Bogerts B. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J. Psychiatr. Res. 2008, 42:868-876.
68. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., Keilhoff G. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience 2008, 154:496-503.
69. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42:151-157.
70. Steiner J., Walter M., Wunderlich M.T., Bernstein H.G., Panteli B., Brauner M., Jacobs R., Gos T., Rothermundt M., Bogerts B. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry 2009, 65:1107-1110.
71. Takagi K., Takagi M., Kanangat S., Warrington K.J., Shigemitsu H., Postlethwaite A.E. Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J. Immunol. 2005, 174:1801-1810.
72. Takano A., Arakawa R., Ito H., Tateno A., Takahashi H., Matsumoto R., Okubo Y., Suhara T. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol. 2010, 13:943-950.
73. Tandon R., Marcus R.N., Stock E.G., Riera L.C., Kostic D., Pans M., McQuade R.D., Nyilas M., Iwamoto T., Crandall D.T. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr. Res. 2006, 84:77-89.
74. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
75. Uranova N.A., Vostrikov V.M., Vikhreva O.V., Zimina I.S., Kolomeets N.S., Orlovskaya D.D. The role of oligodendrocyte pathology in schizophrenia. Int. J. Neuropsychopharmacol. 2007, 10:537-545.
76. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64:820-822.
77. Van Den Bosch L., Tilkin P., Lemmens G., Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002, 13:1067-1070.
78. Van Eldik L.J., Wainwright M.S. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor. Neurol. Neurosci. 2003, 21:97-108.
79. Woodruff R.H., Tekki-Kessaris N., Stiles C.D., Rowitch D.H., Richardson W.D. Oligodendrocyte development in the spinal cord and telencephalon: common themes and new perspectives. Int. J. Dev. Neurosci. 2001, 19:379-385.
80. Xiao L., Xu H., Zhang Y., Wei Z., He J., Jiang W., Li X., Dyck L.E., Devon R.M., Deng Y., Li X.M. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 2008, 13:697-708.
81. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15769-15774.
82. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010.
83. Zhang Y., Xu H., Jiang W., Xiao L., Yan B., He J., Wang Y., Bi X., Li X., Kong J., Li X.M. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res. 2008, 106:182-191.
84. Zhou Z., Peng X., Hao S., Fink D.J., Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther. 2008, 15:183-190.